CORD is Canada's national network for organizations representing all those with rare disorders.

CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. CORD works with governments, researchers, clinicians and industry to promote research, diagnosis, treatment and services for all rare disorders in Canada.

Learn More

Event

GETTING TO ACCESS Innovative approaches to innovative medicines

March 29, 2017
Sheraton Vancouver Wall Centre 1088 Burrard Street, Vancouver, BC
INNOVATIVE MEDICINES OFFER OPPORTUNITIES AND CHALLENGES Why this forum matters: Innovative drug therapies are medicines that can: Offer a substantial improvement over existing therapies; for example, biologics can modify the underlying cause of a condition rather than just treat the symptoms; Address an unmet need; many drugs for rare disease are the first to be developed for that condition Target the (unique) characteristics of a subgroup of patients based on genetic makeup and/or other individual characteristics Cure the disease; for example, by eliminating the cause (hepatitis C virus), replacing abnormal cells (stem cell replacement), or modifying the faulty gene But innovative therapies come at a price that is often considered “unaffordable” under current assessment processes Individually, therapies tend to be much higher than the “old” therapies they are replacing The number of innovative therapies is increasing, as is the impact on drug budgets Our assessment processes do not address innovation; they were developed to determine how much incremental cost should be paid for incremental benefits to existing therapies and how to allocate drug budgets to achieve most overall health of a population, regardless of the conditions and need Individual high-cost therapies can have an identifiable impact on overall drug plan budgets, whether private or public Presented by: Tensions among stakeholders have increased, as have the rhetoric and distrust Regulators have been challenged for approving drugs that lack evidence of clinical effectiveness 

Shares

BECOME A MEMBER

Join us and become part of an active Canadian rare disorder community. The only national organization representing all rare disorder patient groups in Canada.

Individual Membership

For individuals, patients or family members.

Learn More

Affiliate Group Membership

For patient-based organizations, support groups or other charitable groups.

Learn More

Corporate Leaders Membership

For industry (pharmaceutical/biotech) and corporate associations.

Learn More